MHRA Import Rules for Medicines Entering the UK

Quick answer: Importing medicines into the UK legally requires the importer to hold the correct licence for the activity — a Wholesale Dealer’s Licence (WDA(H)) for finished, licensed medicines already authorised in the UK, or a Manufacturer’s/Importer’s Authorisation (MIA) for importing unlicensed or investigational medicinal products. The overseas manufacturing site must also meet a GMP standard the MHRA recognises (UK GMP, EU-GMP, or an equivalent under a Mutual Recognition Agreement), and since Brexit, medicines imported from the EU/EEA into Great Britain generally require an MHRA-recognised Responsible Person for Import (RPi) to confirm ongoing compliance. Every batch also needs correct labelling, a valid marketing authorisation (or an appropriate licensing route if unlicensed), and full audit-trail documentation the MHRA can inspect on request.

If you’re setting up to bring medicines into the UK — whether you’re a wholesale distributor supplying pharmacies, a specialist importer sourcing unlicensed medicines for NHS trusts, or a manufacturer trying to understand what your UK-based customer will actually require from you — the rulebook changed meaningfully after Brexit, and a lot of guidance floating around online is now out of date. This is where things actually stand, and what you need in place before a shipment leaves the origin country.

Key Takeaways

• You need the right licence for the specific activity: a Wholesale Dealer’s Licence for finished, authorised medicines, or an MIA for unlicensed/investigational products.
• Post-Brexit, medicines entering Great Britain from the EU/EEA generally require a Responsible Person for Import (RPi) as part of the compliance chain.
• The manufacturing site needs GMP recognised by the MHRA — UK GMP, EU-GMP, or an equivalent covered under a Mutual Recognition Agreement.
• Northern Ireland operates under different rules from Great Britain due to the Windsor Framework, and the two should never be treated as interchangeable.
• MHRA inspections and batch release checks focus heavily on the paper trail — QP certification, batch documentation, and traceability — not just the physical product.

Why UK Import Rules Look Different From the Rest of Europe Now

Before 2021, importing medicines into the UK largely followed EU pharmaceutical law, since the UK was itself an EU member state. Since Brexit, the UK — specifically Great Britain (England, Scotland, and Wales) — runs its own regulatory regime under the MHRA, separate from the EU’s European Medicines Agency (EMA) framework, while Northern Ireland continues to follow EU medicines rules under the Windsor Framework.

This split matters enormously for anyone sourcing medicines for the UK market, because “the UK” is no longer a single regulatory zone. A product cleared for Great Britain isn’t automatically cleared for Northern Ireland, and vice versa, and the documentation, licensing routes, and even the labelling requirements can differ between the two.

For distributors and importers, this means the very first question before setting up a supply chain isn’t “does this product meet UK requirements” — it’s “which part of the UK is this actually going to, and under which regulatory regime.”

The Core Licences You Need to Understand

Wholesale Dealer’s Licence (WDA(H))

If you’re importing finished, already-licensed medicines (products holding a UK Marketing Authorisation, whether granted by the MHRA directly or recognised via an appropriate pathway) for onward wholesale distribution, you generally need a Wholesale Dealer’s Licence issued by the MHRA. This licence authorises the holder to import, store, and distribute medicinal products at wholesale level, and it comes with binding obligations around Good Distribution Practice (GDP) — appropriate storage conditions, traceability, and a Responsible Person (RP) who oversees compliance for the licence holder.

Manufacturer’s/Importer’s Authorisation (MIA)

If you’re importing unlicensed medicines — for example, specials manufactured for individual patient needs, or investigational medicinal products for clinical trials — a Wholesale Dealer’s Licence isn’t sufficient. This activity typically requires a Manufacturer’s/Importer’s Authorisation, which carries additional obligations, including Qualified Person (QP) oversight for batch certification before release onto the UK market.

Manufacturer’s Importer Authorisation for Investigational Medicinal Products (MIA(IMP))

For medicines imported specifically for use in clinical trials, a distinct authorisation applies — the MIA(IMP) — reflecting the additional controls around investigational products that haven’t yet received full marketing authorisation.

Responsible Person for Import (RPi)

Introduced as part of the post-Brexit regulatory changes, the RPi role applies to medicines imported into Great Britain from the EEA. The RPi is responsible for confirming that imported batches have been manufactured to a standard equivalent to UK requirements and for maintaining the compliance documentation trail associated with each batch. Depending on your supply chain structure, the RPi function may sit with your own organisation or be contracted to a specialist third party.

GMP Recognition: What the MHRA Actually Accepts

A recurring question from overseas manufacturers and their UK-based importers is which GMP certifications the MHRA will actually recognise, since this determines whether a facility can supply the UK market at all without additional inspection.

UK GMP, issued following an MHRA inspection, is the most directly recognised standard, naturally.

EU-GMP, issued by an EU member state’s competent authority, continues to be broadly recognised for medicines entering Great Britain, reflecting the shared regulatory heritage, though ongoing recognition arrangements are worth confirming for your specific product category given how this area has continued to evolve since Brexit.

Mutual Recognition Agreement (MRA) countries — the UK maintains MRAs with a number of countries (including, historically, arrangements inherited from or renegotiated after EU membership) that allow GMP inspections conducted by a trusted overseas regulator to be recognised without requiring a separate UK inspection, provided the agreement covers the relevant product category.

WHO-GMP, while widely recognised across much of the world, is not automatically equivalent to UK GMP recognition on its own. A facility holding only WHO-GMP certification, without EU-GMP, UK GMP, or coverage under an applicable MRA, will typically need to demonstrate GMP compliance through an MHRA-recognised route before its products can be imported into the UK — this is one of the most common gaps that trips up manufacturers used to exporting successfully into WHO-GMP-accepting markets and assuming the same standard opens the UK market automatically.

A Quick Comparison

Step-by-Step: How Medicines Legally Enter the UK Market

1. Confirm Marketing Authorisation Status

Before anything else, confirm whether the specific product holds a valid UK Marketing Authorisation (or qualifies under an appropriate unlicensed medicines route). Products without this status generally cannot be distributed commercially in the UK outside narrow, specifically regulated exceptions.

2. Confirm the Manufacturing Site’s GMP Status

As covered above, confirm the exact manufacturing site producing your specific product holds GMP recognised by the MHRA for the relevant product category — not just a general claim of “GMP certified” without specifying which standard and which authority issued it.

3. Secure the Correct UK-Side Licence

Depending on your role in the supply chain, this means holding (or contracting with a partner who holds) a Wholesale Dealer’s Licence, an MIA, or an MIA(IMP), matched to the specific activity you’re conducting.

4. Appoint a Responsible Person (RP) or Responsible Person for Import (RPi) as Required

For wholesale distribution, an RP oversees GDP compliance. For medicines imported from the EEA into Great Britain, an RPi additionally confirms the imported batch meets the required standard.

5. Prepare Batch-Specific Documentation

Each batch requires a Certificate of Analysis, batch manufacturing and packaging records (or access to them), and, for licensed medicines, confirmation the batch has been through appropriate QP certification before release, where applicable to your import route.

6. Ensure Labelling and Packaging Meet UK Requirements

UK-specific labelling requirements apply, including language requirements, appropriate warnings, and pack information consistent with the product’s Marketing Authorisation. Products labelled solely for a different market rarely meet UK requirements without modification.

7. Submit Import Documentation and Clear UK Customs/MHRA Checks

Shipments move through UK Border Force and customs processes, with MHRA-relevant products subject to additional regulatory checks tied to licensing and GMP documentation where applicable.

Northern Ireland vs. Great Britain: Why You Cannot Treat Them the Same

This is one of the most consequential post-Brexit changes, and it catches out even experienced importers who assume “UK” means one uniform set of rules.

Under the Windsor Framework, Northern Ireland continues to follow EU medicines regulations for many purposes, meaning products entering Northern Ireland are generally subject to EU regulatory requirements, including EU-recognised GMP and, in many cases, EU marketing authorisation frameworks, rather than the Great Britain-specific MHRA licensing regime described above.

Practically, this means a supply chain built around a Great Britain-focused Wholesale Dealer’s Licence and MHRA marketing authorisation route may not automatically satisfy requirements for the same product entering Northern Ireland, and vice versa. Distributors serving both markets need to structure their compliance separately for each, rather than assuming a single licence and documentation package covers the whole of the UK.

What an MHRA Inspection Actually Looks Like

For UK-based licence holders — whether you hold a Wholesale Dealer’s Licence or an MIA — the MHRA doesn’t just review your paperwork once at application stage and disappear. Inspections happen periodically, and for wholesale distributors, they focus heavily on GDP compliance: storage conditions, temperature monitoring records, traceability of individual batches through your warehouse, and whether your Responsible Person genuinely has the authority and visibility the role requires, rather than holding the title without real oversight.

For manufacturing or import sites under an MIA, inspections go further, examining batch release procedures, QP decision-making records, and how deviations and out-of-specification results are investigated and closed. Inspectors will typically walk your premises, review a sample of batch records against physical stock, and interview staff about how procedures work in practice, not just how they’re written down.

At the close of an inspection, findings are typically categorised by severity — critical, major, or other — with critical findings requiring urgent corrective action and carrying real risk to your licence status if not resolved appropriately. Distributors and importers who treat GDP and GMP compliance as continuous operational discipline, rather than something to tidy up before an expected inspection, consistently fare better here, in much the same way manufacturers with genuinely embedded quality systems handle WHO-GMP or FDA inspections more smoothly than those scrambling to reconstruct records after the fact.

How Long Licensing Takes, and What It Costs

Licensing fees themselves are relatively modest compared to the operational cost of maintaining compliant premises, trained staff, a functioning quality system, and — where relevant — an active Responsible Person or Qualified Person on payroll or contract. For smaller distributors weighing whether to build this infrastructure in-house versus partnering with an established licence holder or contracted RP/RPi service, the ongoing compliance overhead is usually the more significant cost driver than the licence application itself.

Common Reasons Shipments Get Held Up

GMP certification that doesn’t match an MHRA-recognised standard. As covered above, this is one of the most frequent gaps — a supplier confidently citing WHO-GMP or another non-directly-recognised certification without the additional documentation UK recognition actually requires.

Missing or incorrect Responsible Person for Import documentation. For EEA-origin imports into Great Britain, gaps in RPi confirmation are a distinctly post-Brexit source of delay that didn’t exist under the old EU-wide framework.

Marketing Authorisation mismatches. A product genuinely authorised in another market isn’t automatically authorised for the UK; confirming an active UK-specific Marketing Authorisation (or appropriate unlicensed route) before shipping is essential, not optional.

Labelling that doesn’t meet UK-specific requirements. Pack information built for a different regulatory market frequently doesn’t satisfy MHRA labelling rules without modification.

Confusing Great Britain and Northern Ireland requirements. Shipping documentation and licensing built around the wrong regulatory regime for the actual destination is a distinctly post-Brexit error that simply didn’t exist as a category of mistake before 2021.

Incomplete batch documentation for QP certification. Where QP release applies, gaps in the documentation trail supporting that certification can hold a batch even when the underlying product quality isn’t in question.

What UK Wholesale Distributors and NHS Procurement Teams Should Verify Before Committing to a Supplier

Confirm the specific GMP standard and issuing authority, not just a general compliance claim, and check whether it falls under direct recognition, an MRA, or requires additional confirmation.

Confirm UK Marketing Authorisation status for the exact product, including strength, formulation, and pack size, since variations aren’t automatically covered under a related authorisation.

Clarify who holds RPi responsibility for EEA-origin imports into Great Britain, and confirm that role is properly documented and active, not assumed.

Request the manufacturer’s most recent inspection history where available, similarly to how you’d approach due diligence with WHO-GMP or FDA-regulated suppliers.

Confirm labelling compliance for the specific UK market segment you’re supplying into (Great Britain versus Northern Ireland), rather than assuming one pack design serves both.

For NHS and public procurement specifically, confirm the supplier meets any additional framework agreement or procurement-specific compliance requirements layered on top of baseline MHRA rules, since NHS trusts often apply additional quality assurance criteria beyond the regulatory minimum.

A Realistic Example of How This Plays Out

Picture a UK wholesale distributor sourcing a generic respiratory medication from a manufacturer that has, until now, exported successfully into several WHO-GMP-recognising markets across Africa and the Middle East. The manufacturer assumes their existing WHO-GMP certification will be sufficient and is surprised when their UK-based distribution partner requests additional documentation.

The distributor’s compliance team explains that WHO-GMP alone doesn’t satisfy MHRA recognition requirements, and asks whether the facility also holds EU-GMP or coverage under an applicable Mutual Recognition Agreement. It turns out the facility does hold EU-GMP certification from a previous inspection cycle tied to supplying an EU-based customer, which the distributor confirms is currently valid and covers the relevant product category.

With that clarified, the distributor moves forward, appoints an RPi to oversee the EEA-to-Great-Britain import chain (since the product will transit through an EU distribution point before reaching the UK), and confirms UK-specific labelling has been prepared separately from the packs used for the manufacturer’s other export markets.

Contrast this with a second scenario, where a different manufacturer offers similar terms but holds only WHO-GMP certification, with no EU-GMP, UK GMP, or MRA-covered inspection history. Moving forward with this supplier for the UK market would require either an additional MHRA-recognised compliance route or, in many cases, isn’t currently viable without further certification work — a gap that’s far better identified during sourcing due diligence than after a shipment has already been booked.

Sample Documentation Checklist for a UK-Bound Shipment

While the exact package varies by licence route and product type, a well-prepared shipment of licensed medicines into Great Britain typically includes:

• Confirmation of active UK Marketing Authorisation for the exact product, strength, and pack size
• Certificate of Analysis specific to the batch
• Batch manufacturing and packaging records, or manufacturer confirmation these are available on request
• Evidence of GMP status at the manufacturing site, specifying the standard and issuing/inspecting authority
• QP certification confirmation, where the import route requires it
• RPi documentation confirming the batch meets a UK-equivalent standard, for EEA-origin imports into Great Britain
• Labelling and packaging matching the approved Marketing Authorisation, in the correct language and format for the destination market
• Wholesale Dealer’s Licence or MIA reference confirming the receiving party is authorised to handle the shipment
• Transport and storage records demonstrating GDP-compliant handling throughout transit

Building this into a standard purchase order and shipping checklist, rather than assembling it reactively, is the single most effective way to avoid the kind of last-minute documentation scramble that turns a routine shipment into a multi-week hold.

Common Misconceptions About UK Medicine Imports

“EU-GMP still automatically covers everything post-Brexit, no changes needed.” Broadly, EU-GMP recognition has continued for many purposes, but the surrounding compliance requirements — RPi obligations, separate UK Marketing Authorisation confirmation, Great Britain versus Northern Ireland distinctions — are genuinely new since 2021 and don’t disappear just because the underlying GMP standard is still recognised.

“A licence to distribute in Great Britain covers Northern Ireland too.” It doesn’t, and this remains one of the most consequential and frequently misunderstood aspects of the post-Brexit framework. Treat the two as separate regulatory destinations requiring separate compliance planning.

“Any recognised GMP certification is equally acceptable to the MHRA.” As covered above, this isn’t accurate. UK GMP, EU-GMP, and MRA-covered inspections sit in a different recognition category than WHO-GMP or other national standards not covered under a specific mutual recognition arrangement.

“Once a Wholesale Dealer’s Licence is granted, ongoing compliance is a formality.” Licences come with binding, ongoing GDP obligations, periodic inspections, and real consequences — including licence suspension or revocation — for serious or repeated non-compliance. It’s a continuous responsibility, not a one-time achievement.

“NHS procurement just follows standard MHRA rules, nothing extra.” Many NHS frameworks and individual trust contracts layer additional supplier accreditation, quality assurance, or traceability requirements on top of baseline regulatory compliance, meaning meeting MHRA requirements alone doesn’t guarantee eligibility for a specific NHS contract.

Importing Unlicensed Medicines (“Specials”) for NHS and Clinical Use

A meaningful share of NHS procurement activity involves unlicensed medicines — products needed for individual patient treatment where no suitably licensed alternative exists, commonly referred to as “specials.” This route sits under different rules from standard licensed medicine imports, and it’s worth understanding separately given how often NHS trusts and specialist importers operate in this space.

Unlicensed medicines can be imported into the UK to meet the special clinical needs of an individual patient, under provisions that exist specifically because no licensed product suitable for that patient’s needs is available. This isn’t a general workaround for importing cheaper unlicensed versions of otherwise available licensed medicines — it’s a narrowly defined clinical necessity pathway, and MHRA guidance is specific about the conditions under which it applies.

Importers operating in this space typically need an MIA (or to work through a licensed importer who holds one), and the sourced product still needs to come from a manufacturing site meeting an appropriate GMP standard, even though the finished product itself doesn’t hold UK marketing authorisation. Documentation requirements are, if anything, more stringent here rather than less, since there’s no marketing authorisation acting as a baseline assurance of the product’s quality and appropriateness — the burden shifts more heavily onto the importer’s own due diligence and the prescriber’s clinical justification.

NHS procurement teams working in this space should pay particular attention to confirming the unlicensed product source facility’s GMP status, the specific clinical necessity justification required for each import, and that the supplying importer holds appropriate MIA authorisation for this specific activity, since it is legally and procedurally distinct from standard wholesale distribution of licensed products.

Choosing Between Holding Your Own Licence and Partnering With an Established Licence Holder

For distributors and importers weighing how to structure UK market entry, there are broadly two paths, and the right choice depends heavily on scale and long-term intent.

Holding your own Wholesale Dealer’s Licence or MIA gives you direct control over the import and distribution chain, but it comes with real, ongoing overhead: premises meeting GDP standards, a genuinely engaged Responsible Person (or Qualified Person for MIA holders), periodic MHRA inspections, and the administrative burden of maintaining compliance documentation continuously rather than just at entry points. For distributors planning sustained, high-volume UK activity, this investment typically pays off in control and margin over time.

Partnering with an established UK licence holder — using their Wholesale Dealer’s Licence, RPi arrangement, or MIA as the regulatory vehicle for your imports — lets you enter the market faster, without building licensing infrastructure from scratch. This is a common approach for overseas manufacturers testing UK market viability, or for smaller distributors who don’t yet have the volume to justify the fixed costs of holding their own licence. The trade-off is less direct control and typically a commercial margin paid to the licence-holding partner for the compliance infrastructure they provide.

Neither path is inherently better — it’s a genuine trade-off between control and speed-to-market, and the right answer usually becomes clear once you have a realistic volume and timeline estimate for your UK activity.

What Changed Specifically After Brexit — A Quick Recap

For anyone who learned UK medicines import rules before 2021 and hasn’t kept up since, the key shifts worth internalising are:

• The MHRA now operates independently of the EMA, running its own marketing authorisation and licensing processes for Great Britain
• The Responsible Person for Import (RPi) role was introduced specifically for EEA-origin imports into Great Britain, with no direct equivalent under the old EU-wide framework
• Northern Ireland diverged from Great Britain under the Windsor Framework, continuing to follow EU medicines regulation rather than the new MHRA-specific regime
• GMP recognition arrangements had to be rebuilt outside the automatic EU-wide mutual recognition that existed while the UK was a member state, replaced by the current mix of direct MHRA recognition, continued EU-GMP recognition, and country-specific MRAs
• Labelling and packaging requirements diverged in places between the UK and EU markets, meaning packs built for one no longer automatically satisfy the other

None of this is exotic once you’ve worked through it once, but it’s a genuinely different landscape from what existed before 2021, and treating it as “basically the same as EU rules with some paperwork changes” is where a lot of avoidable friction still comes from today.

Frequently Asked Questions

Do I need a Wholesale Dealer’s Licence to import medicines into the UK? If you’re importing finished, already-licensed medicines for onward wholesale distribution, yes, you generally need a Wholesale Dealer’s Licence (WDA(H)) issued by the MHRA, along with a designated Responsible Person overseeing compliance.

Is WHO-GMP certification enough to import medicines into the UK? Not automatically. The MHRA directly recognises UK GMP, generally EU-GMP, and GMP inspections from countries covered under applicable Mutual Recognition Agreements. WHO-GMP alone typically requires an additional MHRA-recognised confirmation route before it satisfies UK import requirements.

What is a Responsible Person for Import (RPi)? The RPi is a role introduced after Brexit, applicable to medicines imported into Great Britain from the EEA, responsible for confirming imported batches meet a standard equivalent to UK requirements and maintaining the associated compliance documentation.

Are the import rules the same for Northern Ireland and Great Britain? No. Northern Ireland continues to follow EU medicines regulations under the Windsor Framework, while Great Britain operates under the MHRA’s separate post-Brexit regime. Compliance built for one does not automatically satisfy the other.

What’s the difference between a Wholesale Dealer’s Licence and an MIA? A Wholesale Dealer’s Licence covers the import and distribution of finished, already-licensed medicines. A Manufacturer’s/Importer’s Authorisation (MIA) is required for unlicensed medicines or investigational medicinal products, and carries additional obligations, including Qualified Person oversight for batch release.

How long does it take to get MHRA licensing in place? Timelines vary depending on the licence type and the applicant’s existing compliance infrastructure, but establishing a Wholesale Dealer’s Licence or MIA from scratch typically takes several months, factoring in application review, and in some cases, an inspection of premises before the licence is granted.

Can I import medicines into the UK from a manufacturer that only holds FDA approval? FDA GMP is not automatically recognised as equivalent to UK requirements. Depending on the specific arrangement in place at the time, additional confirmation or a separate MHRA-recognised compliance route may be required before a US-approved product can be imported for the UK market.

What happens if my shipment doesn’t meet MHRA licensing or GMP recognition requirements? The shipment may be held at the border, refused entry, or require the importer to resolve the compliance gap (obtaining appropriate licensing, confirming GMP equivalence, or correcting documentation) before release, similarly to how unresolved compliance issues affect entry into other regulated markets.

Do NHS procurement contracts have additional requirements beyond standard MHRA rules? Often yes. NHS trusts and procurement frameworks frequently layer additional quality assurance, traceability, or supplier accreditation requirements on top of baseline MHRA licensing and GMP recognition, so confirming framework-specific criteria alongside regulatory compliance is worthwhile before bidding on NHS contracts.

Who is responsible for Qualified Person (QP) certification of imported batches? QP certification responsibility sits with the licence holder (typically under an MIA) bringing the product to market, confirming the batch has been manufactured and tested to the required standard before release for sale or supply in the UK.

Can I import unlicensed medicines into the UK for general commercial distribution? No. The unlicensed medicines (“specials”) import route exists specifically to meet the clinical needs of individual patients where no suitably licensed alternative is available, not as a general commercial pathway for distributing unlicensed products more broadly.

Do I need to hold my own Wholesale Dealer’s Licence, or can I partner with an existing licence holder? Both are viable approaches. Holding your own licence gives more direct control but requires ongoing compliance infrastructure and cost. Partnering with an established licence holder or RPi service provider allows faster market entry with less upfront investment, at the cost of reduced direct control over the import chain.

How is Northern Ireland’s medicines regulation different from Great Britain’s? Northern Ireland continues to follow EU medicines regulation under the Windsor Framework, including EU-recognised GMP and marketing authorisation frameworks in many cases, while Great Britain operates under the MHRA’s separate post-Brexit licensing and recognition regime.

Quick-Reference Glossary

MHRA: The Medicines and Healthcare products Regulatory Agency, the UK’s national regulator for medicines and medical devices.

WDA(H): Wholesale Dealer’s Authorisation (Human medicines), the licence required to import and wholesale distribute finished, licensed medicines in the UK.

MIA: Manufacturer’s/Importer’s Authorisation, required for manufacturing or importing unlicensed medicines, carrying QP oversight obligations.

RPi (Responsible Person for Import): A role responsible for confirming medicines imported into Great Britain from the EEA meet a standard equivalent to UK requirements.

QP (Qualified Person): An individual formally responsible for certifying that a batch of medicine has been manufactured and tested in accordance with GMP and the relevant marketing authorisation before release to market.

Windsor Framework: The post-Brexit arrangement governing Northern Ireland’s continued alignment with EU regulations for medicines, distinct from Great Britain’s MHRA-led regime.

Mutual Recognition Agreement (MRA): A formal arrangement between the UK and another country allowing GMP inspections by a trusted overseas regulator to be recognised without a separate UK inspection, within the agreement’s defined scope.

GDP (Good Distribution Practice): Standards governing the appropriate storage, transport, and traceability of medicines throughout the wholesale distribution chain.

Specials: Unlicensed medicines imported or manufactured to meet the special clinical needs of an individual patient where no suitably licensed alternative is available.

Marketing Authorisation: The formal approval required for a medicine to be legally sold or supplied in the UK, confirming it has been assessed for safety, quality, and efficacy for the specific formulation, strength, and indication.

Related Reading for UK-Focused Importers and Distributors

If you’re building a broader compliance checklist across multiple regulated markets, it’s also worth reviewing:

• How WHO-GMP certification works, for suppliers whose facilities don’t yet hold UK-recognised GMP
• US FDA requirements for importing generic medicines, if you’re also sourcing for US-facing supply chains
• TGA regulations for importing pharmaceuticals into Australia
• What a strong pharmaceutical quality agreement should include, regardless of destination market

The Bottom Line

The UK’s post-Brexit medicines import regime rewards precision. It’s no longer enough to confirm a supplier is “GMP certified” in general terms — you need to know exactly which standard, issued by which authority, recognised through which pathway, and whether the destination is Great Britain or Northern Ireland, since the two now run on genuinely different rules. Distributors and NHS procurement teams who build this level of specificity into their sourcing due diligence, rather than relying on broad compliance claims, are the ones who avoid the border delays and licensing gaps that have become distinctly more common — and more consequential — since 2021.

If there’s one habit worth building from everything above, it’s this: ask which GMP standard, ask which authority issued it, and ask which part of the UK your product is actually going to, every single time, before the purchase order goes out rather than after the shipment is already in transit.

For manufacturers new to the UK market, the most efficient starting point is usually a direct conversation with a prospective UK distribution partner about exactly which licence, RPi arrangement, and GMP recognition pathway they expect to see, rather than assuming existing certifications built for other markets will transfer automatically. And for UK-based distributors and NHS procurement teams, the return on investing time in this level of due diligence up front is substantial — a supply chain built on correctly matched licensing and clearly documented GMP recognition rarely produces the kind of border delays, rejected shipments, or compliance disputes that come from assuming one certification fits every market.